Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy
2019276 citationsAlbert M. Maguire, Stephen R. Russell et al.Ophthalmologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Daniel C. Chung
Since
Specialization
Citations
This map shows the geographic impact of Daniel C. Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel C. Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel C. Chung more than expected).
This network shows the impact of papers produced by Daniel C. Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel C. Chung. The network helps show where Daniel C. Chung may publish in the future.
Co-authorship network of co-authors of Daniel C. Chung
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel C. Chung.
A scholar is included among the top collaborators of Daniel C. Chung based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Daniel C. Chung. Daniel C. Chung is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Bennett, Jean, Stephen R. Russell, Katherine A. High, et al.. (2021). Five-Year Post-Injection Results of the Phase 3 Trial of Voretigene Neparvovec-rzyl in Biallelic RPE65 Mutation-Associated Inherited Retinal Disease. Investigative Ophthalmology & Visual Science. 62(8). 3540–3540.3 indexed citations
4.
Chung, Daniel C., Myriam Marussig, Camille Andrieu, et al.. (2021). Correlations between progression markers in rod-cone dystrophy due to mutations in RHO, PDE6A, or PDE6B.. Investigative Ophthalmology & Visual Science. 62(8). 3539–3539.1 indexed citations
5.
Chung, Daniel C., et al.. (2019). Long-term Effect of Voretigene Neparvovec on the Full-Field Light Sensitivity Threshold Test of Patients with RPE65 Mutation-Associated Inherited Retinal Dystrophy – Post Hoc Analysis of Phase I trial data. Investigative Ophthalmology & Visual Science. 60(9). 3398–3398.7 indexed citations
6.
Alemán, Tomás S., Rachel M. Huckfeldt, Leona Serrano, et al.. (2019). AAV2-hCHM Subretinal Delivery to the Macula in Choroideremia: 2 year Results of an Ongoing Phase I/II Gene Therapy Trial. Investigative Ophthalmology & Visual Science. 60(9). 5173–5173.5 indexed citations
7.
Russell, Stephen R., Albert M. Maguire, Jean Bennett, et al.. (2019). Visual Function Questionnaire Responses in the Voretigene Neparvovec Phase 3 Trial. Investigative Ophthalmology & Visual Science. 60(9). 4968–4968.2 indexed citations
8.
Russell, Stephen R., Jean Bennett, Jennifer Wellman, et al.. (2018). Three-year update for the phase 3 voretigene neparvovec study in biallelic RPE65 mutation–associated inherited retinal disease. Investigative Ophthalmology & Visual Science. 59(9). 3900–3900.2 indexed citations
9.
Alemán, Tomás S., Leona Serrano, Grace Han, et al.. (2017). AAV2-hCHM Subretinal Delivery to the Macula in Choroideremia: Preliminary Six Month Safety Results of an Ongoing Phase I/II Gene Therapy Trial. Investigative Ophthalmology & Visual Science. 58(8). 4485–4485.4 indexed citations
10.
Chung, Daniel C., Stephen R. Russell, Jean Bennett, et al.. (2017). Correlation of multi-luminance mobility testing with visual function tests in a phase 3 trial of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease. Investigative Ophthalmology & Visual Science. 58(8). 3292–3292.3 indexed citations
11.
Russell, Stephen R., Jean Bennett, Jennifer Wellman, et al.. (2017). Year 2 results for a phase 3 trial of voretigene neparvovec in biallelic RPE65-mediated inherited retinal disease. Investigative Ophthalmology & Visual Science. 58(8). 4122–4122.6 indexed citations
12.
Reape, Kathleen Z., Daniel C. Chung, Jennifer Wellman, et al.. (2017). Natural History of Individuals with Retinal Degeneration Due to Biallelic Mutations in the RPE65 Gene. Investigative Ophthalmology & Visual Science. 58(8). 1488–1488.2 indexed citations
Morgan, Jessica I. W., Grace Han, Albert M. Maguire, et al.. (2013). Adaptive Optics Scanning Laser Ophthalmoscopy and High Resolution Imaging in Autosomal Dominant Retinitis Pigmentosa Caused by a Novel PRPF31 Nonsense Mutation. Investigative Ophthalmology & Visual Science. 54(15). 3445–3445.1 indexed citations
15.
Morgan, Jessica I. W., Daniel C. Chung, Koji Nozato, Albert M. Maguire, & Jean Bennett. (2012). Imaging Retinal Structure in Patients and Carriers of Choroideremia. Investigative Ophthalmology & Visual Science. 53(14). 4648–4648.3 indexed citations
Chung, Daniel C., et al.. (2009). Recent breakthroughs in gene therapy for inherited retinal degeneration.. PubMed. 8(42). 125–9.3 indexed citations
18.
Chung, Daniel C., et al.. (2008). Externally Regulated AAV-Mediated Delivery of PEDF Ameliorates the OIR Phenotype. Investigative Ophthalmology & Visual Science. 49(13). 1127–1127.2 indexed citations
19.
Chung, Daniel C., Zhengyu Wei, & Jean Bennett. (2006). In vivo Non–Viral Gene Transfer to Retinal Ganglion Cells. Investigative Ophthalmology & Visual Science. 47(13). 836–836.1 indexed citations
20.
Wong, Wai T., Tonia S. Rex, Alberto Auricchio, et al.. (2004). Effect of over-expression of pigment epithelium derived factor (PEDF) on developing retinal vasculature in the mouse.. PubMed. 10. 837–44.10 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.